Huaren Pharmaceutical Co., Ltd. (SHE:300110)

Market Cap	3.40B -3.0%
Revenue (ttm)	1.33B +6.2%
Net Income	-462.97M
EPS	-0.39
Shares Out	1.18B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,265,460
Average Volume	23,143,254
Open	2.980
Previous Close	2.940
Day's Range	2.870 - 2.990
52-Week Range	2.820 - 3.750
Beta	0.36
RSI	33.11
Earnings Date	Apr 24, 2026

About Huaren Pharmaceutical

Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. The company offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. It also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, anti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,491
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300110

Financial Performance

In 2025, Huaren Pharmaceutical's revenue was 1.32 billion, a decrease of -2.34% compared to the previous year's 1.35 billion. Losses were -462.90 million, -66.17% less than in 2024.